Company profile
Inhibrx Biosciences, Inc.
NASDAQ:INBXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Ordastobart | phase2_3 | — | 1 | active |
| Ozekibart | phase2 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06295731 | phase2_3 | active_not_recruiting | 2024-05-14 | 2029-05-01 | Inhibrx Biosciences, Inc | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC |
| NCT03715933 | phase1 | recruiting | 2018-10-08 | 2028-12-01 | Inhibrx Biosciences, Inc | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
| NCT03815396 | phase1 | completed | 2019-07-19 | 2022-08-18 | Inhibrx Biosciences, Inc | Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency |
| NCT03809624 | phase1 | terminated | 2019-01-30 | 2024-10-03 | Inhibrx Biosciences, Inc | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer |
| NCT04198766 | phase1_2 | recruiting | 2019-12-10 | 2033-07-01 | Inhibrx Biosciences, Inc | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) |
FDA applications (0)
No records yet.